Hansa Biopharma's Idefirix (imlifidase) Receives NICE Recommendation as Desensitization Treatment for Highly Sensitized Kidney Transplant Patients
- NICE has recommended Hansa’ Idefirix as a clinically and cost-effective treatment to enable transplantation for highly sensitized kidney transplant patients in England, Wales, and Northern Ireland before kidney transplant from a deceased donor
- Hansa will collaborate with national health service commissioners to support the service's implementation, following NICE recommendations
- Imlifidase has the potential to specifically target & cleave all classes of IgG Abs & is being evaluated in the 4 P-II trials to evaluate the efficacy and safety as a pre-transplant treatment to reduce donor-specific IgG. The therapy has also received marketing authorization in the EU in Aug 2020
Ref: PR Newswire | Image: Hansa
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.